# Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects

> **NCT00119587** · PHASE3 · COMPLETED · sponsor: **Amgen**

## Conditions studied

- Anemia

## Interventions

- **DRUG:** darbepoetin alfa

## Key facts

- **NCT ID:** NCT00119587
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** 2003-09
- **Target enrollment:** — (—)
- **Last updated:** 2007-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00119587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00119587, "Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00119587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*